Invention Grant
US08501693B2 Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
失效
使用毒蜥外泌肽和毒蜥外泌肽激动剂和GLP-1受体激动剂来改变纤维蛋白原的浓度
- Patent Title: Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
- Patent Title (中): 使用毒蜥外泌肽和毒蜥外泌肽激动剂和GLP-1受体激动剂来改变纤维蛋白原的浓度
-
Application No.: US12375734Application Date: 2007-08-06
-
Publication No.: US08501693B2Publication Date: 2013-08-06
- Inventor: Dennis Kim , Michael Trautmann
- Applicant: Dennis Kim , Michael Trautmann
- Applicant Address: US CA San Diego US DE Wilmington
- Assignee: Amylin Pharmaceuticals, LLC,Astrazeneca Pharmaceuticals LP
- Current Assignee: Amylin Pharmaceuticals, LLC,Astrazeneca Pharmaceuticals LP
- Current Assignee Address: US CA San Diego US DE Wilmington
- Agency: Womble Carlyle Sandridge & Rice, LLP
- Agent Mark J. Pino; Alireza Behrooz
- International Application: PCT/US2007/017621 WO 20070806
- International Announcement: WO2008/019147 WO 20080214
- Main IPC: A61K38/36
- IPC: A61K38/36 ; A61K38/00
Abstract:
The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.
Public/Granted literature
Information query
IPC分类:
